Argenx stock (BE:ARGX) $(ARGX)$ tumbled over 30% in premarket trading.
The company said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of using efgartigimod subcutaneous in adults with pemphigus vulgaris and pemphigus foliaceus. The company said it will not pursue additional development in pemphigus and plans to prioritize clinical development of efgartigimod in its ongoing severe autoimmune indications.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments